Safety and Efficacy of Ledipasvir–Sofosbuvir With or Without Ribavirin for Chronic Hepatitis C in Children Ages 6‐11
Sign Up to like & getrecommendations! Published in 2018 at "Hepatology"
DOI: 10.1002/hep.30123
Abstract: Currently, there are no interferon‐free treatments available for hepatitis C virus (HCV)–infected patients younger than 12 years. We evaluated the safety and effectiveness of the all‐oral regimen ledipasvir–sofosbuvir ± ribavirin in HCV‐infected children aged 6… read more here.
Keywords: hepatitis; hcv; safety; sofosbuvir ... See more keywords
Sofosbuvir plus Daclatasvir with or without ribavirin for treatment of chronic HCV genotype 4 patients: real-life experience
Sign Up to like & getrecommendations! Published in 2018 at "Hepatology International"
DOI: 10.1007/s12072-018-9861-2
Abstract: IntroductionNew regimens involving direct-acting antiviral agents have recently been approved for the treatment of HCV. Our aim was to assess the efficacy and safety of 12 or 24 weeks of Sofosbuvir 400 mg plus Daclatasvir 60 mg, with… read more here.
Keywords: genotype patients; treatment; receiving weeks; without ribavirin ... See more keywords
Daclatasvir, sofosbuvir with or without ribavirin for 24 weeks in hepatitis C genotype 3 cirrhosis: A real-life study.
Sign Up to like & getrecommendations! Published in 2019 at "Annals of hepatology"
DOI: 10.1016/j.aohep.2018.09.005
Abstract: INTRODUCTION AND AIM Cirrhotic patients with hepatitis C virus genotype 3 infection show unsatisfactory outcomes after 12 weeks' treatment with direct antiviral agents. The National Italian Drug Agency allows 24 weeks of therapy in difficult-to-treat… read more here.
Keywords: without ribavirin; study; hepatitis; hepatology ... See more keywords
Sofosbuvir‐Daclatasvir is suboptimal in patients with genotype 2 chronic hepatitis C infection: real‐life experience from the HEPATHER ANRS CO22 cohort
Sign Up to like & getrecommendations! Published in 2020 at "Journal of Viral Hepatitis"
DOI: 10.1111/jvh.13321
Abstract: Sofosbuvir plus daclatasvir with or without ribavirin has demonstrated a high efficacy and an acceptable safety profile in clinical trials of patients infected with genotype 2 hepatitis Cvirus (HCV); however, there are currently no real‐world… read more here.
Keywords: without ribavirin; daclatasvir; sofosbuvir daclatasvir; daclatasvir without ... See more keywords